These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 3663313)
41. Flow cytometric DNA measurements in human thyroid tumors. Christov K Virchows Arch B Cell Pathol Incl Mol Pathol; 1986; 51(3):255-63. PubMed ID: 2874658 [TBL] [Abstract][Full Text] [Related]
42. Diagnostic and prognostic utility of flow cytometric DNA measurements in follicular thyroid tumors. Grant CS; Hay ID; Ryan JJ; Bergstralh EJ; Rainwater LM; Goellner JR World J Surg; 1990; 14(3):283-9; discussion 289-90. PubMed ID: 2368430 [TBL] [Abstract][Full Text] [Related]
44. Relationship among 201T1 uptake, nuclear DNA content and clinical behavior in metastatic thyroid carcinoma. Nakada K; Katoh C; Morita K; Kanegae K; Tsukamoto E; Shiga T; Mochizuki T; Tamaki N J Nucl Med; 1999 Jun; 40(6):963-7. PubMed ID: 10452311 [TBL] [Abstract][Full Text] [Related]
45. DNA aneuploidy in follicular thyroid neoplasia. Cusick EL; Ewen SW; Krukowski ZH; Matheson NA Br J Surg; 1991 Jan; 78(1):94-6. PubMed ID: 1998875 [TBL] [Abstract][Full Text] [Related]
46. Flow cytometric DNA analysis combined with fine needle aspiration biopsy in the diagnosis of palpable metastases. Joensuu H; Klemi PJ; Eerola E Anal Quant Cytol Histol; 1988 Aug; 10(4):256-60. PubMed ID: 3166671 [TBL] [Abstract][Full Text] [Related]
47. Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma. Chiappetta G; Tallini G; De Biasio MC; Manfioletti G; Martinez-Tello FJ; Pentimalli F; de Nigris F; Mastro A; Botti G; Fedele M; Berger N; Santoro M; Giancotti V; Fusco A Cancer Res; 1998 Sep; 58(18):4193-8. PubMed ID: 9751634 [TBL] [Abstract][Full Text] [Related]
48. Dipeptidyl aminopeptidase IV staining of cytologic preparations to distinguish benign from malignant thyroid diseases. Aratake Y; Kotani T; Tamura K; Araki Y; Kuribayashi T; Konoe K; Ohtaki S Am J Clin Pathol; 1991 Sep; 96(3):306-10. PubMed ID: 1715126 [TBL] [Abstract][Full Text] [Related]
49. Diagnostic value of DNA flow cytometry combined with fine needle aspiration biopsy in lymphomas. Joensuu H; Klemi PJ; Eerola E J Pathol; 1988 Mar; 154(3):237-45. PubMed ID: 3351670 [TBL] [Abstract][Full Text] [Related]
50. Image analysis of papillary thyroid carcinoma fine-needle aspirates: significant association between aneuploidy and death from disease. Sturgis CD; Caraway NP; Johnston DA; Sherman SI; Kidd L; Katz RL Cancer; 1999 Jun; 87(3):155-60. PubMed ID: 10385447 [TBL] [Abstract][Full Text] [Related]
51. Flow cytometric DNA-analysis of cells obtained with fine needle aspiration biopsy of the breast. Niezabitowski A; Lackowska B; Gruchala A; Ryś J; Jaszcz A; Szklarski W; Wasilewska A; Herman K Gen Diagn Pathol; 1996 Jun; 142(1):33-9. PubMed ID: 8793484 [TBL] [Abstract][Full Text] [Related]
52. Diagnostic utility of DNA content flow cytometry in follicular neoplasms of the thyroid. Harlow SP; Duda RB; Bauer KD J Surg Oncol; 1992 May; 50(1):1-6. PubMed ID: 1573886 [TBL] [Abstract][Full Text] [Related]
53. Fine needle aspirates of follicular lesions of the thyroid gland. The intermediate-type smear. Ravinsky E; Safneck JR Acta Cytol; 1990; 34(6):813-20. PubMed ID: 2256417 [TBL] [Abstract][Full Text] [Related]
54. The diagnostic value of flow cytometric DNA measurements in follicular tumors of the thyroid gland. Greenebaum E; Koss LG; Elequin F; Silver CE Cancer; 1985 Oct; 56(8):2011-8. PubMed ID: 4027931 [TBL] [Abstract][Full Text] [Related]
55. The diagnostic value of flow cytometric DNA measurements in selected disorders of the human thyroid. Johannessen JV; Sobrinho-Simões M; Lindmo T; Tangen KO Am J Clin Pathol; 1982 Jan; 77(1):20-5. PubMed ID: 7055095 [TBL] [Abstract][Full Text] [Related]
56. Expression of keratin 19 distinguishes papillary thyroid carcinoma from follicular carcinomas and follicular thyroid adenoma. Schelfhout LJ; Van Muijen GN; Fleuren GJ Am J Clin Pathol; 1989 Nov; 92(5):654-8. PubMed ID: 2479256 [TBL] [Abstract][Full Text] [Related]
58. Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms. Inohara H; Honjo Y; Yoshii T; Akahani S; Yoshida J; Hattori K; Okamoto S; Sawada T; Raz A; Kubo T Cancer; 1999 Jun; 85(11):2475-84. PubMed ID: 10357421 [TBL] [Abstract][Full Text] [Related]
59. Correlation of thyroid fine-needle aspiration with final histopathology: a case series. Gürkan Dumlu E; Kiyak G; Bozkurt B; Tokaç M; Polat B; Cakir B; Güler G; Kiliç M Minerva Chir; 2013 Apr; 68(2):191-7. PubMed ID: 23612233 [TBL] [Abstract][Full Text] [Related]
60. Parotid gland lesions: diagnosis of malignancy with MRI and flow cytometric DNA analysis and cytology in fine-needle aspiration biopsy. Takashima S; Takayama F; Wang Q; Kurozumi M; Sekiyama Y; Sone S Head Neck; 1999 Jan; 21(1):43-51. PubMed ID: 9890350 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]